REDWOOD CITY, Calif., Sept. 01, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS) today announced that senior management will present at three upcoming investor healthcare conferences.
  • Management participation in a fireside chat is scheduled at the Wells Fargo Healthcare Conference on Wednesday, September 6 th at 8:30 a.m. ET taking place in Boston, MA.
  • Management participation in a fireside chat is scheduled at the Baird 2017 Global Healthcare Conference on Thursday, September 7 th at 9:05 a.m. ET taking place in New York, NY.
  • A company presentation is scheduled at Cantor Fitzgerald's 3 rd Annual Healthcare Conference on Tuesday, September 26 th at 8:35 a.m. ET taking place in New York, NY.

The audio portion of the presentations will be available on the investors page of the Coherus BioSciences website at

About Coherus BioSciences, Inc.Coherus is a leading pure-play, global biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales & marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-1420 (adalimumab biosimilar) and CHS-0214 (etanercept biosimilar), as well as developing a robust pipeline of future products in four therapeutic areas, oncology, immunology (anti-TNF), ophthalmology and multiple sclerosis. For additional information, please visit
CONTACT:Patrick O'BrienSenior Vice President, Investor RelationsCoherus BioSciences, (650) 649-3527

Primary Logo